ClinicalTrials.gg
RecruitingNCT06533852LiverGutUpdated Jul 20, 2026

Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis

A Phase 3 interventional study of Fecal Microbiome Transplantation (FMT) and FMT Placebo in Decompensated Cirrhosis, sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER). Recruiting at 8 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase III, multicenter, double-blind, placebo-controlled, randomized clinical trial to evaluate the safety and efficacy of Fecal Microbiota Transplantation (FMT) from healthy subjects to patients with decompensated cirrhosis.

02

Conditions studied

  • Decompensated Cirrhosis
03

In context

Lead sponsor

Consorcio Centro de Investigación Biomédica en Red (CIBER) is the lead sponsor of 18 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old.
  2. Cirrhosis defined by standard clinical criteria, ultrasonographic findings and/or histology. Cirrhosis of any etiology may be included except from patients with cirrhosis due to hepatitis, and patients with cirrhosis due to cholestatic liver disease can only be included in the study if they present clinical decompensation of cirrhosis (i.e. ascites).
  3. B or C patients (7- up to 12 points).
  4. Women of * must have a negative pregnancy test in serum before the inclusion in the study and agree to use highly effective methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence** (only if refraining from heterosexual intercourse during the period of twelve months). Hormonal contraceptive methods will be avoided due to the risk of adverse events and impairment of liver function.

Exclusion criteria

Exclusion Criteria:

  1. Previous history of gastrointestinal surgery or colorectal cancer.
  2. Patients with previous history of intestinal obstruction or those who are at increased risk of this complication.
  3. Active Clostridium Difficile infection.
  4. Patients on treatment with non-selective beta-blockers for \<3 month or without stable doses.
  5. Patients on treatment with any drugs.
  6. Patients on antiviral therapy for or those who have received it within the last 12 months.
  7. Patients on antiviral therapy for therapy for \< 12 months.
  8. Patients with hepatocellular carcinoma, except for patients with early HCC (BCLC-0 or BCLC-A) or patients with previous history of HCC and absence of recurrence 2 years after treatment.
  9. Patients admitted to the hospital for acute decompensation of the disease. These patients could be included after discharged as long as they do not present any of the following events:

    1. Bacterial infection within 10 days before study inclusion.
    2. Gastrointestinal bleeding within 10 days before study inclusion.
    3. Current overt hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy according to the New-Haven classification.
  10. Patients with ACLF according to the criteria published by Moreau et al. (Appendix 1).
  11. Severe alcoholic hepatitis requiring therapy (MELD > 20) in the last 6 months.
  12. Patients with active alcohol consumption of more than 21 units per week.
  13. infection.
  14. Patients with a history of significant extra hepatic disease with impaired short-term prognosis, including congestive heart failure Grade III/IV, GOLD >2, chronic kidney disease with serum creatinine >2mg/dL or under renal replacement therapy.
  15. Patients with current extra hepatic including solid tumours and hematologic disorders.
  16. Patients with previous organ transplantation.
  17. Pregnancy or breastfeeding.
  18. Patients included in other clinical trials in the month before inclusion.
  19. Patients with mental incapacity, language barrier, bad social support or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study.
  20. Refusal to give .
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    Fecal Microbiome Transplantation (FMT)

    A first dose of 24 capsules of FMT at baseline and a second dose of 24 capsules of FMT at 3 months. Each dose (24 capsules) contains approximately 50g of stool.

    Drug: Fecal Microbiome Transplantation (FMT)

  • Placebo comparator
    FMT Placebo

    A first dose of 24 capsules of FMT placebo at baseline and a second dose of 24 capsules of FMT placebo at 3 months. Each dose (24 capsules) contains in total 6 g of microcrystalline cellulose or equivalent.

    Other: FMT Placebo

Interventions

  • DrugFecal Microbiome Transplantation (FMT)

    Two doses: First dose: 24 capsules of FMT at baseline. Second dose: 24 capsules of FMT at 3 months.

  • OtherFMT Placebo

    Two doses: First dose: 24 capsules of FMT placebo at baseline. Second dose: 24 capsules of FMT placebo at 3 months.

06

What researchers measure

Primary outcomes

  1. Efficacy of treatment in halting the progression of decompensated cirrhosis.

    Assessed by time to first decompensation event (acute kidney injury (AKI), ascites, bacterial infection, gastrointestinal bleeding, HE).

    Time frame: Screening to month 12.

Secondary outcomes

  1. Time to transplant-free survival

    Assessed by transplant-free survival

    Time frame: At month 1, month 3, month 6 and month 12

  2. Mortality rates

    Assessed by mortality rates

    Time frame: At month 1, month 3, month 6 and month 12

  3. Rate of patients developing/ worsening individual complications of cirrhosis.

    Assessed by ascites, acute kidney injury, bacterial infections, gastrointestinal bleeding and hepatic encephalopathy.

    Time frame: At baseline, month 1, month 3, month 6 and month 12.

  4. Frequency of hospital admissions due to complications of cirrhosis.

    Assessed by hospital admissions due to complications of cirrhosis.

    Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.

  5. Development of acute-on-chronic liver failure (ACLF)

    Assessed by time to first episode of ACLF

    Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.

  6. Development of acute-on-chronic liver failure (ACLF)

    Assessed by total number of patients developing ACLF

    Time frame: At month 3, month 6 and month 12.

  7. Development of acute-on-chronic liver failure (ACLF)

    Assessed by severity of ACLF episodes based on ACLF grade (from grade 1 to grade 3) and CLIF-C-ACLF score

    Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.

  8. Development of acute-on-chronic liver failure (ACLF)

    Assessed by number and type of organ failures

    Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.

  9. Changes from baseline in systemic inflammatory response.

    Evaluated by measurement in a large array of plasma cytokine levels including, but not limited to TNFα, IL-6, IL8, IL-10, IL-1β, IFN-ɣ, G-CSF, VCAM, VEGF, as well as an oxidized form of albumin, human nonmercaptalbumin-2 (HNA2).

    Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.

  10. PBMCs phenotype and function.

    Analysed by flow cytometry, functional analysis, and RNAseq single cell analysis.

    Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.

  11. Changes from baseline in different plasma and urine prognostic biomarkers.

    Measurated by different plasma and urine prognostic biomarkers including, but not only, copeptin, NGAL, PD-L1, L-FABP.

    Time frame: At baseline, 1 month, 3 months, 6 months, and 12 months.

  12. Changes from baseline in systemic hemodynamics and vasoactive hormones.

    Measurated by systemic hemodynamics and vasoactive hormones: plasma renin concentration and plasma copeptin.

    Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.

  13. Changes from baseline in blood levels of bacterial DNA or bacterial products.

    Measurated by blood levels of bacterial DNA or bacterial products.

    Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.

  14. Changes from baseline in liver function.

    Evaluated by MELD (Model for End-stage Liver Disease) score.

    Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.

  15. Changes from baseline in liver function.

    Evaluated by CLIF-AD score.

    Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.

  16. Changes from baseline in liver function.

    Evaluated by Child Pugh Score.(from 1 point to 15 points)

    Time frame: At baseline, 1 month, 3 months, 6 months and 12 months.

  17. Analyze microbiome composition from saliva and stool.

    Measurated by analysis of microbial genes.

    Time frame: At baseline, and months 1, 3 and 6.

  18. Changes in hepatic venous pressure gradient (HVPG) from baseline.

    Measurated by the hepatic venous pressure gradient.

    Time frame: At baseline and month 6.

  19. Assess Quality of life, functional assessment and in Minimal Hepatic Encephalopathy.

    Evaluated with data obtained from CLDQ (Chronic Liver Disease Questionnaire) questionnaire.

    Time frame: At baseline, 3 months, 6 months and 12 months.

  20. Assess Quality of life, functional assessment and in Minimal Hepatic Encephalopathy.

    Evaluated with data obtained from Liver Frailty Index.

    Time frame: At baseline, 3 months, 6 months and 12 months.

  21. Assess Quality of life, functional assessment and in Minimal Hepatic Encephalopathy.

    Evaluated with data obtained from PHES (Psychometric Hepatic Encephalopathy Score) questionnaire.

    Time frame: At baseline, 3 months, 6 months and 12 months.

  22. Changes from baseline in AUDIT test.

    Evaluated from AUDIT test

    Time frame: AUDIT test at baseline, 3 months, 6 months and 12 months

  23. Changes from baseline in alcohol consumption.

    Evaluated from PETh measurament.

    Time frame: PETh measurament test at baseline, 1 month, 3 months, 6 months and 12 months.

  24. Assess the effect of FMT in ECG (Electrocardiogram).

    Evaluated by changes in ACE score.

    Time frame: At screening, baseline and months 3,6 and 12.

  25. Proportion of patients with treatment-related adverse events.

    Evaluated by treatment-related adverse events.

    Time frame: Screening to month 12.

  26. Proportion of patients with severe treatment-related adverse events.

    Evaluated by treatment-related adverse events.

    Time frame: Screening to month 12.

07

Study locations

8 of 8 sites recruiting
  • Hospital Clínic de Barcelona
    Barcelona, Spain
    Recruiting
    • Pere Gines Gibert, MD-PhD · Principal investigator
    • Adria Juanola Mayos, MD-PhD · Principal investigator
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Spain
    Recruiting
    • German Soriano Pastor, MD-PhD · Principal investigator
  • Hospital Universitari Vall Hebron
    Barcelona, Spain
    Recruiting
    • Isabel Campos Varela, MD-PhD · Principal investigator
  • Hospital General Universitario Gregorio Marañón
    Madrid, Spain
    Recruiting
    • Rafael Bañares Cañizares, MD-PhD · Principal investigator
  • Hospital General Universitario Puerta de Hierro
    Madrid, Spain
    Recruiting
    • Carlos Fernández Carrillo, MD-PhD · Principal investigator
  • Hospital Universitario Ramón y Cajal
    Madrid, Spain
    Recruiting
    • Agustion Albillos Martínez, MD-PhD · Principal investigator
  • Corporació Sanitaria Universitaria Parc Taulí
    Sabadell, Spain
    Recruiting
    • Cristina Solé Martó, MD-PhD · Principal investigator
  • Hospital Universitario Marqués de Valdecilla
    Santander, Spain
    Recruiting
    • Jose Ignacio Fortea Ormachea, MD-PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jan 2029, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Aug 1, 2024
StartActual
Jul 16, 2025
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06533852
Lead sponsor
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Jul 16, 2025
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Jul 20, 2026

Study contacts

Eva Bonfill
Contact
BONFILL@recerca.clinic.cat
+34932275400 ext. 4198

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion